BMS Follows Merck’s Lead, Sues Government Over Drug Pricing Negotiation

Bristol Myers Squibb (BMS) has filed a lawsuit against the Biden administration, following in Merck's footsteps, claiming that an upcoming Medicare drug negotiation program violates the First and Fifth Amendments of the U.S. Constitution. The company alleges that if the drug price negotiation program comes into force, it would force pharma companies to give big discounts to Medicare and sell the..